Document is current
Any future updates will be listed below
-
Authors
Souren, Laura
Ihorst, Gabriele
Greil, Christine
Engelhardt, Monika
Wäsch, Ralph
-
Funding
Funding for this research was provided by:
Universitätsklinikum Freiburg
- License Information
-
More Information
Article History
Received: 7 June 2024
Accepted: 3 September 2024
First Online: 23 September 2024
Declarations
:
: The study is registered at Freiburg Register of Clinical Trials under protocol FRKS004511 and was approved by the Ethics Committee of the University of Freiburg (EV 23-1110_1-S1). It was performed according to the guidelines of the Declaration of Helsinki and Good Clinical Practice.
: All patients gave their written informed consent for institutionally initiated research studies in accordance with the institutional review board guidelines.
: RW consulted for Amgen, BMS/Celgene, Janssen, Novartis, Kite/Gilead, Pfizer, Sanofi and Takeda, he received research funding from Janssen and Sanofi, and travel support from Janssen, Kite/Gilead, Pfizer and BMS. The other authors declare no competing financial interest related to this study.
